Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Selective targeting of M2-like tumor-associated macrophages by TB511 promotes NK cell-associated antitumor immunity in prostate cancer

Abstract

Prostate cancer progression is strongly influenced by the tumor immune microenvironment, in which M2-like tumor-associated macrophages (TAMs) promote immune suppression and tumor growth. Although TAM-targeted therapies have emerged as promising immunomodulatory strategies, the downstream immune effector mechanisms associated with tumor suppression after M2-like TAM targeting remain incompletely defined. Here, we investigated whether TB511, an M2-like TAM-targeting peptide-drug conjugate, suppresses prostate tumor growth by remodeling the M2-like TAM compartment and promoting NK cell-associated antitumor immunity. TIMER3.0 analysis of human prostate adenocarcinoma datasets showed increased expression of M2-like TAM-associated genes and reduced expression of several NK cell-associated genes in tumor tissues compared with normal prostate tissues. In immunocompetent TRAMP-C2 and RM-1 syngeneic prostate cancer models, TB511 significantly reduced tumor growth and tumor burden. TB511 selectively decreased F4/80+CD206+ M2-like macrophages without significantly reducing F4/80+CD86+ M1-like macrophages, increased the M1/M2 macrophage ratio, and suppressed M2-associated immunosuppressive genes, including ARG1, CD163, TGFB, and IL10. TB511 also increased CD8+ T-cell and NK cell infiltration, enhanced NCR1-positive cells, increased GZMB-expressing NK-associated cytotoxic cells, increased NK-associated effector genes, and decreased the inhibitory receptor-associated genes NKG2A and TIGIT. In contrast, TB511 failed to suppress TRAMP-C2 tumor growth in immunodeficient NSG mice, supporting an immune-dependent component of its antitumor activity. Immune cell depletion experiments further revealed that CD8 T-cell depletion did not abolish TB511-mediated tumor suppression, whereas NK1.1+ cell depletion eliminated the antitumor effect of TB511. Notably, TB511 still reduced M2-like macrophages under NK1.1+ cell-depleted conditions, indicating that macrophage remodeling alone is insufficient for tumor control without NK1.1+ cells. These findings demonstrate that TB511 suppresses prostate tumor growth by selectively reducing M2-like TAMs and promoting NK cell-associated cytotoxic antitumor immunity, with NK1.1+ cells required for therapeutic efficacy. TB511 may represent a promising immunomodulatory peptide-drug conjugate for targeting the M2-like TAM-NK cell axis in prostate cancer.

Related

  1. Tumor immune cell targeting chimeras reprogram tumor-associated macrophages
    Mariko Morimoto, David S. Roberts, Ru M. Wen +6
    Nature Chemical BiologyPeer-reviewedLicence not statedFull text7 citedImmunologyOpenAlex
  2. Precision targeting of tumor-associated macrophages via a 6-substituted pyrrolo[2,3-d]pyrimidine chimeric molecule for enhanced cancer immunotherapy
    Yining Zhang, Binghao Guo, Lixiao Guo +16
    Communications ChemistryPeer-reviewedCC BY-NC-ND 4.0Full textImmunologyCrossref
  3. CAR T cell targeting of inflammatory myeloid progenitors in the bone marrow remodels border-associated macrophages and reverses cognitive aging
    A. S. Harris, J. A. Rouse, G. Guo +12
    bioRxivPreprintCC BYFull textCell biologybioRxiv
  4. Targeting O-GlcNAcylation in tumor-associated macrophages: from metabolic reprogramming to osteolytic niche formation in bone-invasive solid tumors
    Shengqian Li, Yuan Zhi, Shaoming Li +6
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyCrossref
  5. SEC31A promotes gastric cancer progression by inducing the PI3K/AKT/mTOR pathway and enhancing the CCL5-mediated M2 polarization and recruitment of tumor-associated macrophages
    Xixian Zhao, Liuye Huang
    Oncology ReportsPeer-reviewedCC BY-NC-ND 4.0Full textImmunologyPMC
BibTeX
@article{han2026selective,
  title = {{Selective targeting of M2-like tumor-associated macrophages by TB511 promotes NK cell-associated antitumor immunity in prostate cancer}},
  author = {Ik-Hwan Han and DaeHwan Park and Jihwan Moon and Chaeyoung Kwon and Hyunsu Bae},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.1938334},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1938334},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Selective targeting of M2-like tumor-associated macrophages by TB511 promotes NK cell-associated antitumor immunity in prostate cancer
AU  - Ik-Hwan Han
AU  - DaeHwan Park
AU  - Jihwan Moon
AU  - Chaeyoung Kwon
AU  - Hyunsu Bae
PY  - 2026
DA  - 2026/11/10
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1938334
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1938334
AB  - Prostate cancer progression is strongly influenced by the tumor immune microenvironment, in which M2-like tumor-associated macrophages (TAMs) promote immune suppression and tumor growth. Although TAM-targeted therapies have emerged as promising immunomodulatory strategies, the downstream immune effector mechanisms associated with tumor suppression after M2-like TAM targeting remain incompletely defined. Here, we investigated whether TB511, an M2-like TAM-targeting peptide-drug conjugate, suppresses prostate tumor growth by remodeling the M2-like TAM compartment and promoting NK cell-associated antitumor immunity. TIMER3.0 analysis of human prostate adenocarcinoma datasets showed increased expression of M2-like TAM-associated genes and reduced expression of several NK cell-associated genes in tumor tissues compared with normal prostate tissues. In immunocompetent TRAMP-C2 and RM-1 syngeneic prostate cancer models, TB511 significantly reduced tumor growth and tumor burden. TB511 selectively decreased F4/80+CD206+ M2-like macrophages without significantly reducing F4/80+CD86+ M1-like macrophages, increased the M1/M2 macrophage ratio, and suppressed M2-associated immunosuppressive genes, including ARG1, CD163, TGFB, and IL10. TB511 also increased CD8+ T-cell and NK cell infiltration, enhanced NCR1-positive cells, increased GZMB-expressing NK-associated cytotoxic cells, increased NK-associated effector genes, and decreased the inhibitory receptor-associated genes NKG2A and TIGIT. In contrast, TB511 failed to suppress TRAMP-C2 tumor growth in immunodeficient NSG mice, supporting an immune-dependent component of its antitumor activity. Immune cell depletion experiments further revealed that CD8 T-cell depletion did not abolish TB511-mediated tumor suppression, whereas NK1.1+ cell depletion eliminated the antitumor effect of TB511. Notably, TB511 still reduced M2-like macrophages under NK1.1+ cell-depleted conditions, indicating that macrophage remodeling alone is insufficient for tumor control without NK1.1+ cells. These findings demonstrate that TB511 suppresses prostate tumor growth by selectively reducing M2-like TAMs and promoting NK cell-associated cytotoxic antitumor immunity, with NK1.1+ cells required for therapeutic efficacy. TB511 may represent a promising immunomodulatory peptide-drug conjugate for targeting the M2-like TAM-NK cell axis in prostate cancer.
SN  - 1664-3224
ER  -